Personal therapeutics startup Vineti, Inc. announced it has closed on a $35 million Series C funding round.
This new funding round was led by Cardinal Health, with participation from various investors including Novartis Pharma AG, Giliead Company backed Kite, Canaan Partners, Threshold Ventures, Section 32, LifeForce Capital, Casdin Capital and Hive Ventures.
Vineti plans to add representatives from Cardinal Health to its board of directors, along with representatives from Novartis and Kite, who will join as board observers.
Vineti will use the new capital to expand its platform, the only one of record to enable both clinical and commercial personalized therapeutics into other high-value, high-complexity therapeutic supply chains. The funding will also support Vineti’s continued expansion in Europe and Asia-Pacific, expanding its software solutions around the world.
Vineti was co-founded by CE and the Mayo Clinic to provide a cloud-based platform to expand patient access to life-saving cell and gene therapies.